| Experiment ID | EXP00321 |
| Reference | Title: Circulating micro-RNAs as potential blood-based markers for early stage breastcancer detection. Author: Schrauder MG, Strick R, Schulz-Wendtland R, Strissel PL, Kahmann L, LoehbergCR, Lux MP, Jud SM, Hartmann A, Hein A, Bayer CM, Bani MR, Richter S, AdamietzBR, Wenkel E, Rauh C, Beckmann MW, Fasching PA. Journal: PLoS One. 2012;7(1):e29770. doi: 10.1371/journal.pone.0029770. Epub 2012 Jan 5. Abstract: INTRODUCTION: MicroRNAs (miRNAs, miRs) are a class of small, non-coding RNAmolecules with relevance as regulators of gene expression thereby affectingcrucial processes in cancer development. MiRNAs offer great potential asbiomarkers for cancer detection due to their remarkable stability in blood andtheir characteristic expression in many different diseases. We investigatedwhether microarray-based miRNA profiling on whole blood could discriminatebetween early stage breast cancer patients and healthy controls.METHODS: We performed microarray-based miRNA profiling on whole blood of 48 earlystage breast cancer patients at diagnosis along with 57 healthy individuals ascontrols. This was followed by a real-time semi-quantitative Polymerase ChainReaction (RT-qPCR) validation in a separate cohort of 24 early stage breastcancer patients from a breast cancer screening unit and 24 age matched controlsusing two differentially expressed miRNAs (miR-202, miR-718).RESULTS: Using the significance level of p<0.05, we found that 59 miRNAs weredifferentially expressed in whole blood of early stage breast cancer patientscompared to healthy controls. 13 significantly up-regulated miRNAs and 46significantly down-regulated miRNAs in our microarray panel of 1100 miRNAs andmiRNA star sequences could be detected. A set of 240 miRNAs that was evaluated byradial basis function kernel support vector machines and 10-fold cross validationyielded a specificity of 78.8%, and a sensitivity of 92.5%, as well as anaccuracy of 85.6%. Two miRNAs were validated by RT-qPCR in an independent cohort.The relative fold changes of the RT-qPCR validation were in line with themicroarray data for both miRNAs, and statistically significant differences inmiRNA-expression were found for miR-202.CONCLUSIONS: MiRNA profiling in whole blood has potential as a novel method forearly stage breast cancer detection, but there are still challenges that need to be addressed to establish these new biomarkers in clinical use. PMID: 22242178 |
| Expressiion Profile | Description: miRNA expression profiling in early stage breast cancer Organism: Homo sapiens GEO ID: GSE31309 Platform: GPL14132 Number of samples: 105 |
| Design and Sample | Cancer Type: breast cancer Cancer SubType: invasive ductal carcinoma Cell Line: N/D Experimental Design: blood Case Sample: blood from breast cancer Control Sample: normal blood Num of Case: 48 Num of Control: 57 Quantification Software: limma Num of miRNAs: 1100 |
| Identification | Num of Up: 31 Num of Down: 39 |